Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,899.40 today based on a price of $781.99 for LLY at the time of writing.

Some key growth products include the oncology drug Verzenio and immunology drug Taltz, which accounted for 9% and 6% of total ...

I'm a growth and value investor, and Eli Lilly slots perfectly into the nexus of my strategy. With 12-month upside of 30-50% in a base-bull case, not buying Eli Lilly stock now is foolish.